FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229076003> ?p ?o ?g. }

• W4229076003 endingPage "103706" @default.
• W4229076003 startingPage "103706" @default.
• W4229076003 abstract "Evaluating trends in HCV treatment and prevalence is crucial for monitoring elimination. We evaluated the change in current infection and treatment among people who inject drugs (PWID) between 2018-2019 and 2019-2021. ETHOS Engage is an observational cohort study of PWID attending drug treatment clinics and needle and syringe programs in Australia. Participant enrolment occurred over two periods, Wave 1 (May 2018-September 2019, 25 sites) and Wave 2 (November 2019-June 2021, 21 sites), with baseline questionnaire completion and point-of-care HCV RNA testing (Xpert® HCV Viral Load Fingerstick). Logistic regression was used to identify factors associated with current HCV infection and historic HCV treatment. 2,395 individuals were enrolled across the two recruitment waves (66% male, median age 43, 72% current opioid agonist therapy, and 65% injecting in the previous month). HCV prevalence decreased from 24% to 17% between 2018-2019 and 2019-2021, respectively (p=0.003). HCV treatment increased from 66% to 74% between 2018-2019 and 2019-2021, respectively (p<0.001). After adjusting, there was a reduction in current HCV infection in 2019-2021 (adjusted odds ratio [aOR] 0.62; 95% CI, 0.50, 0.77) compared to 2018-2019. Other factors associated with current infection included homelessness (aOR, 1.70; 1.26, 2.30), incarceration (vs. never; historic: aOR 1.69; 95%CI 1.31, 2.19; recent: aOR 1.85; 95%CI, 1.35, 2.54), and recently injecting drugs (vs. >12 months ago; previous month <daily: aOR 2.03; 95%CI, 1.37, 3.02; ≥daily: aOR 2.90; 95%CI, 1.94, 4.32). The increase in HCV treatment and decrease in prevalence among PWID provides evidence of further progress towards HCV elimination; however, sub-populations may require additional support to enhance elimination. PWID are a priority population to facilitate HCV elimination and temporal data are crucial to understand trends in HCV infection and treatment in this group. Among a cohort of PWID recruited during two different waves and in an era of unrestricted DAA therapy, prevalence of HCV infection decreased and the proportion who had received HCV treatment increased. Sub-populations of PWID—including people who are homeless, people who have been incarcerated, people who frequently inject drugs, younger people, women, and people not engaged in OAT—may require additional support to enhance HCV elimination efforts." @default.
• W4229076003 created "2022-05-08" @default.
• W4229076003 creator A5001207210 @default.
• W4229076003 creator A5006875478 @default.
• W4229076003 creator A5008990660 @default.
• W4229076003 creator A5010049089 @default.
• W4229076003 creator A5010998752 @default.
• W4229076003 creator A5029267264 @default.
• W4229076003 creator A5032658269 @default.
• W4229076003 creator A5037358261 @default.
• W4229076003 creator A5041369213 @default.
• W4229076003 creator A5042359443 @default.
• W4229076003 creator A5045529959 @default.
• W4229076003 creator A5050284793 @default.
• W4229076003 creator A5051184153 @default.
• W4229076003 creator A5052909853 @default.
• W4229076003 creator A5052916430 @default.
• W4229076003 creator A5054648799 @default.
• W4229076003 creator A5067193474 @default.
• W4229076003 creator A5067459141 @default.
• W4229076003 creator A5076492591 @default.
• W4229076003 creator A5081388535 @default.
• W4229076003 creator A5083113156 @default.
• W4229076003 creator A5089050608 @default.
• W4229076003 creator A5090747493 @default.
• W4229076003 creator A5091736605 @default.
• W4229076003 date "2022-07-01" @default.
• W4229076003 modified "2023-09-23" @default.
• W4229076003 title "Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study" @default.
• W4229076003 cites W1493231842 @default.
• W4229076003 cites W2068035436 @default.
• W4229076003 cites W2115399503 @default.
• W4229076003 cites W2117027295 @default.
• W4229076003 cites W2119593462 @default.
• W4229076003 cites W2160638691 @default.
• W4229076003 cites W2579682140 @default.
• W4229076003 cites W2620881498 @default.
• W4229076003 cites W2755647730 @default.
• W4229076003 cites W2787655189 @default.
• W4229076003 cites W2789574679 @default.
• W4229076003 cites W2883551899 @default.
• W4229076003 cites W2888082412 @default.
• W4229076003 cites W2898222507 @default.
• W4229076003 cites W2898580126 @default.
• W4229076003 cites W2901859453 @default.
• W4229076003 cites W2903249677 @default.
• W4229076003 cites W2919155466 @default.
• W4229076003 cites W2936861866 @default.
• W4229076003 cites W2969821228 @default.
• W4229076003 cites W2987157692 @default.
• W4229076003 cites W2987885479 @default.
• W4229076003 cites W2988242616 @default.
• W4229076003 cites W2990999638 @default.
• W4229076003 cites W3013073417 @default.
• W4229076003 cites W3024076667 @default.
• W4229076003 cites W3027264454 @default.
• W4229076003 cites W3048332638 @default.
• W4229076003 cites W3083769626 @default.
• W4229076003 cites W3083848623 @default.
• W4229076003 cites W3085785957 @default.
• W4229076003 cites W3087152772 @default.
• W4229076003 cites W3106187707 @default.
• W4229076003 cites W3109176633 @default.
• W4229076003 cites W3119634101 @default.
• W4229076003 cites W3132126495 @default.
• W4229076003 cites W3134741282 @default.
• W4229076003 cites W3155385798 @default.
• W4229076003 cites W3160551159 @default.
• W4229076003 cites W3164359205 @default.
• W4229076003 cites W3170806830 @default.
• W4229076003 cites W3179045562 @default.
• W4229076003 cites W4220994910 @default.
• W4229076003 doi "https://doi.org/10.1016/j.drugpo.2022.103706" @default.
• W4229076003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35533635" @default.
• W4229076003 hasPublicationYear "2022" @default.
• W4229076003 type Work @default.
• W4229076003 citedByCount "7" @default.
• W4229076003 countsByYear W42290760032022 @default.
• W4229076003 countsByYear W42290760032023 @default.
• W4229076003 crossrefType "journal-article" @default.
• W4229076003 hasAuthorship W4229076003A5001207210 @default.
• W4229076003 hasAuthorship W4229076003A5006875478 @default.
• W4229076003 hasAuthorship W4229076003A5008990660 @default.
• W4229076003 hasAuthorship W4229076003A5010049089 @default.
• W4229076003 hasAuthorship W4229076003A5010998752 @default.
• W4229076003 hasAuthorship W4229076003A5029267264 @default.
• W4229076003 hasAuthorship W4229076003A5032658269 @default.
• W4229076003 hasAuthorship W4229076003A5037358261 @default.
• W4229076003 hasAuthorship W4229076003A5041369213 @default.
• W4229076003 hasAuthorship W4229076003A5042359443 @default.
• W4229076003 hasAuthorship W4229076003A5045529959 @default.
• W4229076003 hasAuthorship W4229076003A5050284793 @default.
• W4229076003 hasAuthorship W4229076003A5051184153 @default.
• W4229076003 hasAuthorship W4229076003A5052909853 @default.
• W4229076003 hasAuthorship W4229076003A5052916430 @default.
• W4229076003 hasAuthorship W4229076003A5054648799 @default.
• W4229076003 hasAuthorship W4229076003A5067193474 @default.
• W4229076003 hasAuthorship W4229076003A5067459141 @default.

• next